COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02840760
Recruitment Status : Unknown
Verified June 2017 by Shanghai Mental Health Center.
Recruitment status was:  Recruiting
First Posted : July 21, 2016
Last Update Posted : February 26, 2018
Information provided by (Responsible Party):
Shanghai Mental Health Center

Brief Summary:
The purpose of this study is to explore the therapeutic effect and mechanism of transcranial magnetic stimulation (rTMS) in the treatment of the tardive dyskinesia.

Condition or disease Intervention/treatment Phase
Tardive Dyskinesia Device: Repetitive Transcranial Magnetic Stimulation Not Applicable

Detailed Description:
The study was a parallel control design trial for 2 weeks. Patients with schizophrenia were treated with 10-Hz rTMS on left motor cortex (added to the ongoing treatment). Clinical symptoms and MEP were assessment before and after rTMS treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
Actual Study Start Date : September 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Active Comparator: tardive dyskinesia group
tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex(M1).
Device: Repetitive Transcranial Magnetic Stimulation
Stimulate the primary motor cortex for 2 weeks.

No Intervention: Healthy control group

Primary Outcome Measures :
  1. Change from baseline in motor evoked potential(MEP) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]
  2. Change from baseline in Abnormal Involuntary Movement Scale(AIMS) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]

Secondary Outcome Measures :
  1. Change from baseline in cortical silent period [ Time Frame: 2 times (Before treatment,immediately after treatment) ]
  2. Change from baseline in short interval intracortical inhibition(SICI) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]
  3. Change from baseline in intracortical facilitation(ICF) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]
  4. Change from baseline in Simpson-Angus Scale(SAS) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]
  5. Change from baseline in Barnes Akathisia Rating Scale(BARS) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]
  6. Change from baseline in Positive and Negative Syndrome Scale(PANSS) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]
  7. Change from baseline in clinical global impression (CGI) [ Time Frame: 2 times (Before treatment,immediately after treatment) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • The diagnosis of schizophrenia according to DSM-IV;
  • At least two item of Abnormal Involuntary Movement Scale(AIMS) must be 2 points or higher
  • these symptoms are not from Parkinson,tourette's syndrome,huntington disease
  • Signed an informed consent

Exclusion Criteria:

  • rTMS contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure
  • patients to be diagnosed according to DSM-IV for substance abused, development delayed
  • current treatment with anticonvulsant acting drugs such as anticonvulsants, benzodiazepines
  • Acute risk of suicide and impulse
  • history of epileptic seizures or the presence of epileptic activity documented on the basis of EEG
  • pregnant and lactant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02840760

Layout table for location contacts
Contact: Dengtang Liu +86 21 64387250-73775

Layout table for location information
China, Shanghai
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine Recruiting
Shanghai, Shanghai, China, 200030
Contact: Dengtang Liu, MD    +862164387250-73775   
Sponsors and Collaborators
Shanghai Mental Health Center
Layout table for additonal information
Responsible Party: Shanghai Mental Health Center Identifier: NCT02840760    
Other Study ID Numbers: 15ZR1435600
First Posted: July 21, 2016    Key Record Dates
Last Update Posted: February 26, 2018
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Shanghai Mental Health Center:
tardive dyskinesia.
Additional relevant MeSH terms:
Layout table for MeSH terms
Tardive Dyskinesia
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Dyskinesia, Drug-Induced